| Indicators | Browse All

Drugs Made In America Acquisition II Corp. (DMIIR)

New York, United States | NasdaqGM
0.08 USD

Short-term:⯪☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 4:42 a.m. EDT

This shell company presents a catastrophic short-term outlook due to a complete lack of liquidity, with trading volume effectively zero and the price stuck at its 52-week low. The balance sheet is fundamentally broken, showing negative book value, negative operating cash flow, and a current ratio well below 1.0, indicating imminent insolvency risks. There is no dividend to speak of, and the recent news highlights a massive rights expiration in 2030 rather than operational success. Long-term prospects are non-existent as the entity has no revenue history, no operational track record, and appears to be a dormant vehicle awaiting a merger that has not materialized. The statistical models correctly flag insufficient data, confirming that there is no mathematical basis for a trade here.

None

Info Dump

Attribute Value
Address1 420 Lexington Avenue
Address2 Suite 1402
Ask 0.1
Ask Size 5
Bid 0.0651
Bid Size 1
Book Value -0.28
City New York
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.081
Current Ratio 0.528
Custom Price Alert Confidence HIGH
Day High 0.081
Day Low 0.081
Display Name Drugs Made In America Acquisition II
Ebitda Margins 0.0
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Two Week High 0.081
Fifty Two Week High Change 0.0
Fifty Two Week High Change Percent 0.0
Fifty Two Week Low 0.081
Fifty Two Week Low Change 0.0
Fifty Two Week Low Change Percent 0.0
Fifty Two Week Range 0.081 - 0.081
Financial Currency USD
Float Shares 50,258,026
Full Exchange Name NasdaqGM
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,025-12-03
Language en-US
Long Business Summary Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
Long Name Drugs Made In America Acquisition II Corp.
Market us_market
Market State POSTPOST
Max Age 86,400
Message Board Id finmb_1938104325
Net Income To Common 8,584,197
Open 0.081
Operating Cashflow -1,110,690
Operating Margins 0.0
Phone 917 982 4565
Previous Close 0.081
Price Hint 4
Price To Book -0.28928572
Profit Margins 0.0
Quick Ratio 0.522
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0
Regular Market Change Percent 0.0
Regular Market Day High 0.081
Regular Market Day Low 0.081
Regular Market Day Range 0.081 - 0.081
Regular Market Open 0.081
Regular Market Previous Close 0.081
Regular Market Price 0.081
Regular Market Time 1,783,713,600
Regular Market Volume 3
Sand P52 Week Change 0.20847368
Sector
Sector Key
Short Name Drugs Made In America Acquisiti
Source Interval 15
State NY
Symbol DMIIR
Total Cash 347,720
Total Cash Per Share 0.005
Total Debt 450,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 3
Zip 10,170